News & Updates

Early intratracheal budesonide does little to improve outcomes in preemies

Early intratracheal budesonide in extremely preterm infants receiving surfactant for respiratory distress syndrome appears to be of little to no benefit in terms of survival free of bronchopulmonary dysplasia (BPD), according to a study.

COVID-19 revisited: Where does nirmatrelvir/ritonavir fit?

At a Pfizer-sponsored symposium held during WONCA Asia Pacific Conference 2024 in Singapore, renowned experts discussed COVID-19 vaccines and highlighted the need for effective antivirals in high-risk groups, including for older adults, with a special focus on the oral antiviral pill nirmatrelvir/ritonavir.

Obesity linked to heightened risk of sleep-related breathing disorders in kids

Children with obesity face an increased risk of sleep-related breathing disorders, similar to those with Prader-Willi syndrome, as reported in a retrospective study.

Simultaneous COVID-19 and influenza testing can protect high-risk groups

COVID-19 and influenza continue to pose severe public health challenge post-pandemic.

Rapid diagnostic tests that can differentiate between COVID-19 and influenza are essential for accurate diagnosis, care, and treatment.^1,2

Over 39M people could die from superbugs by 2050

More than 39 million people worldwide could die from antibiotic-resistant infections from 2025 to 2050 as the superbug crisis intensifies, according to a new global analysis of antimicrobial resistance.

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

New-gen robotic bronchoscopy safe, effective for peripheral pulmonary lesions

A second-generation robotic electromagnetic navigation (EMN) bronchoscopic platform combined with integrated digital tomosynthesis (DT) demonstrates acceptable safety and high diagnostic yield for small peripheral lung nodules, results of the first-in-human study have shown.

Aumolertinib ups PFS in EGFR-mutated NSCLC

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024. 

Original New Drug Application Approvals by US FDA (16-31 October 2024)

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.